StockTipsArenaBeta

BUY Akums Drugs and Pharmaceuticals — Ansh Jogendra Bhilwar

BUYAkums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals share price target & all analyst calls

byAnsh Jogendra BhilwarHorizon: NA (inferred Swing (≤2wk))10 Aug 2026via Zee Business (Live)

Entry₹710.1Inferred
Target₹735
Total upside +3.51% (call closed)
Stop loss₹679-4.38% risk
Exit₹73510 Aug 2026, 9:40 am
Target hit+3.51%0.00%upside left
Follow Ansh Jogendra Bhilwar for new calls(25% target hit, 52 closed calls)Get alertsWatch AKUMS for new buy/sell callsGet alertsSee 1 active Swing call on AKUMSSee 169 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Aug 2026
2 supporting2 neutral0 opposing
Supports the BUY call (2)

Akums Drugs and Pharmaceuticals Ltd reported robust Q1 FY27 financial results with a 13.9% YoY revenue growth to ₹1,167 crore. EBITDA increased by 35.4% to ₹175 crore, and PAT grew to ₹101 crore. The

BSE · Company Update·8 Aug · yesterday

(opens in new tab)

Akums Drugs and Pharmaceuticals reported a 13.9% YoY revenue growth in Q1 FY27 to ₹1,167 crore. PAT increased by 55.4% to ₹101 crore, with EBITDA up 35.4% to ₹175 crore. The CDMO business was the prim

NSE · Press Release·8 Aug · yesterday

(opens in new tab)
Neutral / worth noting (2)

Un-audited Financial Results for the Quarter ended 30th June, 2026

BSE · Board Meeting·8 Aug · yesterday

(opens in new tab)

Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·8 Aug · yesterday

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Akums Drugs and Pharmaceuticals

All analyst calls on Akums Drugs and Pharmaceuticals

More from Ansh Jogendra Bhilwar

Every call and its outcome